Linaclotide is a short peptide drug that most people have never heard described as a peptide at all, despite being one of the most widely prescribed gut medications in the United States. It's a useful example of a peptide designed specifically to stay out of the bloodstream.
What It Is
Linaclotide is a synthetic 14-amino acid peptide, sold under the brand name Linzess in the United States (Constella in parts of Europe and Canada). It was developed by Ironwood Pharmaceuticals and is now marketed by AbbVie. Structurally, it's designed to mimic guanylin and uroguanylin, naturally occurring peptides that regulate fluid secretion in the intestine.
Regulatory Status and Approved Uses
Linaclotide received FDA approval in 2012 and is indicated for two related but distinct conditions in adults: irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). It's taken once daily, at least 30 minutes before the first meal of the day.
How It Works
Linaclotide is a guanylate cyclase-C (GC-C) agonist. It binds to GC-C receptors on the lining of the intestine, which triggers a signaling cascade that increases fluid secretion into the gut and speeds up transit time. Because the peptide acts on receptors located on the intestinal lining itself, very little of it is absorbed into the bloodstream, which is a meaningfully different mechanism from most oral drugs and is part of why its side effects are concentrated in the gastrointestinal tract rather than systemic.
What the Research Shows
Linaclotide's approval rested on multiple randomized, placebo-controlled Phase 3 trials in adults with IBS-C and CIC, measuring standardized outcomes like complete spontaneous bowel movement frequency and abdominal pain scores. It has one of the more substantial human clinical trial records of any peptide covered on this site, consistent with its status as a mainstream, widely prescribed FDA-approved drug rather than a research-only compound.
Safety Considerations
The most common side effect by a wide margin is diarrhea, which can be severe enough in some patients to require stopping the drug. Linaclotide carries an FDA boxed warning: it is contraindicated in patients under 6 years old because of a risk of serious dehydration, based on deaths observed in young animals in nonclinical studies, and it should be avoided in patients ages 6 to 17 for the same reason. It is not approved for use in children. Anyone with a bowel obstruction should not take it, and patients should talk to their doctor if diarrhea becomes severe or if they are pregnant or breastfeeding, since data in those populations is limited.
How It Compares to Other Constipation Treatments
Linaclotide is one of several GC-C agonists and secretagogue-class drugs now approved for chronic constipation and IBS-C, alongside drugs like plecanatide, which works through a similar receptor mechanism, and lubiprostone, which uses a different chloride-channel pathway entirely. Compared to simple osmotic laxatives, linaclotide's appeal is that it's approved specifically for IBS-C with abdominal pain as part of the labeled indication, not just constipation on its own, reflecting the separate trial endpoints the FDA required for that population.
The Bottom Line
Linaclotide is a mainstream, well-studied FDA-approved peptide drug, not a research-chemical gray-market compound, and its local mechanism of action in the gut is a useful illustration of how differently a peptide can behave depending on where in the body it's designed to act. Its most important safety consideration is the pediatric boxed warning, which anyone using it in a household with young children should be aware of.